Article

Schepens to join MEEI

In a move that the institutions say will create the world?s largest ophthalmology research center, Schepens Eye Research Institute will become part of the Massachusetts Eye and Ear Infirmary (MEEI) on June 30. Schepens will remain a non-profit entity and will retain its name, but both institutions will operate under the direction of the MEEI board of directors.

Boston-In a move that the institutions say will create the world’s largest ophthalmology research center, Schepens Eye Research Institute will become part of the Massachusetts Eye and Ear Infirmary (MEEI) on June 30.

Schepens will remain a non-profit entity and retain its name, but both institutions will operate under the direction of the MEEI board of directors.

According to Schepens Eye Research Institute, this union will enrich both its basic research and the clinical research performed at MEEI.

“This creates a powerhouse in vision research that we are confident will accelerate the eradication of blinding diseases,” said Wycliffe “Wyc” Grousbeck, chairman of MEEI’s board of directors.

“Together, we will cover the spectrum of scientific disciplines and eye diseases,” said Joan W. Miller, MD, chairwoman of ophthalmology at MEEI and Harvard Medical School and a member of the Ophthalmology Times editorial advisory board. “Massachusetts Eye and Ear has strong research programs in retina, glaucoma, and genomics. Schepens Eye Research Institute is a world leader in ocular surface disease, immunology, stem cell therapies, regeneration, and mobility rehabilitation. Working together, we will provide an even stronger basic and translational science engine with a powerful clinical team to produce an environment that is primed to solve the problems of and find cures for blinding eye diseases.”

Both Schepens Eye Research Institute and MEEI are Harvard Medical School teaching affiliates. They will be located on one campus in downtown Boston.

“This scientifically rich and diverse alliance will have a powerful impact on our ability to attract the best and the brightest young scientists as well as encourage other seasoned world-class eye researchers to join us in our fight to eradicate devastating [eye] diseases,” said Kenneth Fischer, president and chief operating officer of Schepens Eye Research Institute.“ And it will increase our joint capacity to obtain funding from federal and industry sources.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.